NAT10 and neoplasm: From a translational perspective, advancing NAT10-targeted therapies requires addressing the limitations of current inhibitors: optimizing Remodelin’s structure to enhance specificity for NAT10, improving pharmacokinetics, and developing tumor-selective delivery systems to minimize systemic toxicity.